We report here a very rare case of chronic myeloid leukemia (CML) 
Introduction

Second malignant neoplasms are important late appearing complications after chemotherapy and/or radiotherapy in cancer patients. Therapy-related malignancies include acute leukemia, myelodysplastic syndrome (MDS), Hodgkin's lymphoma, non-Hodgkin's lymphoma, and solid tumors. On the other hand, chronic myeloid leukemia (CML) as a secondary malignancy has rarely been reported. We present here a patient with CML following 5´-deoxy-5-fluorouridine (5´-DFUR) therapy for gastric cancer.
Case Report
.
The types of TRL associated with antimetabolites are MDS or AML, the as same as alkylating agents or topoisomerase-II inhibitors. At present, the incidence of anti-metabolite-related TRL is unknown, but it is obviously lower than the proportion of leukemias following treatment with alkylating agents or topoisomerase-II inhibitors. Some anti-metabolites are given not only for patients with malignant diseases, but also for non-malignant conditions such as rheumatoid arthritis, psoriasis, sarcoidosis, and myasthenia gravis (6-8). Therefore, the question of whether anti-metabolites may cause TRL is important, especially for patients with non-malignant diseases which tend to require long-term use of drugs. The present case is the first reported case of CML following 5´-DFUR treatment. 5´-DFUR is an oral fluoropyrimidines. It is not effective itself but it becomes active only after conversion to 5-FU by pirimidine nucleoside phosphorylase, which is preferentially located in tumor tissues (9). Thus, 5´-DFUR produces a higher level of 5-FU in the tumor site than in the normal counterpart (10).
There are 6 case reports of CML following fluoropyrimidines such as 5-FU and S-1. These cases including our case are summarized in Table 1 (11) (12) (13) (14) (15) (16) T a b l e 1 . T h e r a p y -r e l a t e d Ch r o n i c My e l o i d L e u k e mi a ( CML ) F o l l o wi n g F l u o r o p y r i mi d i n 
